Forty Seven enters trial collaborations with Merck KGAA and Genentech
Executive Summary
Forty Seven Inc. entered into trial collaborations with Merck KGAA and Genentech Inc. to evaluate its own antibody Hu5F9G4 as a potential combination therapy for ovarian and bladder cancers and leukemia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice